Tra­vere fails to con­vince reg­u­la­tors to con­sid­er ac­cel­er­at­ed ap­proval for a rare kid­ney dis­ease — again

As the old say­ing goes, ‘If at first you don’t suc­ceed, try, try again.’ The ori­gin of this mantra is dis­put­ed but has been wide­ly at­trib­uted to Robert the Bruce, the first king of Scot­land, as he and his army did bat­tle with in­vad­ing Eng­lish forces in the ear­ly 14th cen­tu­ry.

But what hap­pens if you try a sec­ond time and again don’t suc­ceed?

Tra­vere Ther­a­peu­tics will be ask­ing it­self that ques­tion af­ter a sec­ond at­tempt to gun for ac­cel­er­at­ed ap­proval was re­ject­ed by the FDA, the com­pa­ny an­nounced Wednes­day af­ter­noon. The for­mer Mar­tin Shkre­li biotech had at­tempt­ed to push through its lead drug, sparsen­tan, to a speedy OK in a rare kid­ney dis­ease, but reg­u­la­tors pre­fer the more me­thod­i­cal, full ap­proval route.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER